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a b s t r a c t
Systemic mastocytosis (SM) includes a wide spectrum of clonal disorders characterized by
an abnormal growth and accumulation of mast cells. SM may be associated with other
hematological neoplasms (SM-AHN) among them the myeloproliferative neoplasms and
myelodysplastic syndromes are the most common. The coexistence of SM with lymphoid
malignancies has rarely been reported so far. The occurrence of SM associated with mul-
tiple myeloma (MM) is extremely rare and its prognosis remains unclear. The treatment of
SM-AHM requires an individual approach. We report a male patient diagnosed with indo-
lent SM associated with MM. He did not require the therapy for his SM, but started the
treatment against MM. He received the induction regiment consisting of bortezomib, thali-
domide and dexamethasone (VTD). After six cycles of VTD he achieved a very good partial
response, but refused autologous stem cell transplantation as response consolidation and
eventually died of myeloma progression a couple months later. Herein we discuss the
likely pathophysiologic mechanisms underlying those two separate entities.
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Mastocytosis represents a group of heterogeneous dis-
eases characterized by clonal proliferation and accumula-
tion of mast cells (MCs) in various organs. The 2016
revision of the World Health Organization (WHO) classifi-
cation distinguishes three major categories of SM: cuta-
neous mastocytosis (CM), systemic mastocytosis (SM), and
MC sarcoma. SM is divided into five subtypes: indolent
systemic mastocytosis (ISM), smoldering systemic masto-
cytosis, SM with an associated hematological neoplasm* Corresponding author. Silesian Medical University, 40-758 Katowice,
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z o.o. All rights reserved.(SM-AHN), aggressive systemic mastocytosis (ASM) and
mast cell leukemia (MCL) [1]. CM affects children and may
be present as maculopapular rash. Other forms of CM
include diffuse cutaneous mastocytosis (DCM) and masto-
cytoma of skin. SM is usually seen in adults and is
defined by multifocal MC aggregates in the bone marrow
or other extracutaneous organs. The true incidence of SM
remains uncertain and is estimated to be approximately
1 case per 10 000/annually [2]. The presence of at least
one of C-findings (cytopenia, lytic lesions, malabsorption,
liver insufficiency and hypersplenism) is sufficient for
treatment initiation. Poland.
w, Instytut Hematologii i Transfuzjologii. Published by Elsevier Sp.
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a combination of symptoms characteristic for each separate
disorder. Chronic myelomonocytic leukemia (CMML) is
reported to be the most common myeloid neoplasm asso-
ciated with SM [4]. Lymphoproliferative neoplasms are
much less commonly involved. To date, there have been
10 reported cases of non-Hodgkin lymphomas, 3 of chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma,
1 of hairy cell leukemia (HCL), and 1 of Hodgkin lymphoma
(HL). SM associated with multiple myeloma (MM) has been
documented in only 8 patients so far [5]. Herein, we describe
a patient with indolent SM associated with MM.
Case report
A 62-year-old male was admitted to Hematology Unit
presenting weakness and fatigue, being febrile (37.9 8C) with
moderate pallor. He also complained of right ankle joint
pain. He was non-atopic and denied a history of anaphy-
laxis, syncope, angioedema or aspirin hypersensitivity. His
past medical history was insignificant. His complete blood
count revealed severe normocytic normochromic anemia
(hemoglobin; Hb; 6.9 g/dL) with a white blood cell (WBC)
count of 16 G/L. Peripheral blood smear revealed slight
anisocytosis with predominance of eosinophils (23%). The
proportion of other cells was within normal range. Biochem-
istry and coagulation tests were normal. Serum immunoglo-
bulin test revealed an elevated IgG level of 37.8 g/L (range
7–16), with normal levels of IgM and IgA. Serum protein
electrophoresis (SPE) detected a monoclonal protein at 2.4 g/
dL defined as IgG lambda on immunofixation. Beta-2 micro-
globulin and C-reactive protein levels were increased at
3.06 mg/L and 26.7 mg/L, respectively. Serum albumin was
decreased: 3.2 g/dL. Serum free lambda and kappa light
chains ratio was 0.12 (range 0.26–1.65). Urine protein electro-
phoresis was negative. X-ray skeletal survey detected
numerous lytic lesions in thoracic and lumbar spine as well
as in pelvis. His spleen was slightly increased (13.4 cm on
abdominal ultrasound).Fig. 1 – Flow cytometry study of bone marrow aspirate before an
Clonal plasma cells (1.6%) were present on flow cytometry analys
lambda and CD56. FITC indicates fluorescein isothiocyanate. MaBone marrow aspirate showed 13% of plasma cells, some
of them with immature appearance. Flow cytometry analy-
sis revealed more than 1.6% of clonal plasma cells with
CD38 and CD138 positivity. No other abnormalities have
been detected (Fig. 1). Bone marrow trephine biopsy was
carried out, but the results were pending.
Conventional cytogenetic study revealed normal karyo-
type, no abnormalities were found by fluorescence in situ
hybridization. The diagnosis of MM was established at stage
IIA (Durie/Salmon staging system) and ISS 2 (International
Staging System).
The patient started the induction with bortezomib, thali-
domide and dexamethasone (VTD) regimen. Meanwhile, the
results of trephine biopsy were available. Marrow was found
to be hypercellular with focal reticulin and collagen fibrosis
(Masson+). Immunohistochemistry revealed atypical CD117+,
tryptase+ cells in clusters comprising 20% of total bone
marrow cellularity. Megakaryocytes were quantitatively nor-
mal, however, a subset of them was hypolobated. Plasma
cells (CD38+, CD138+) constituted 3% of total BM cellularity.
The patient continued his VTD cycles. The extended diagnos-
tic panel toward SM was initiated and revealed an elevated
serum tryptase levels (457 ng/L, range <11.4) and the pre-
sence of a point mutation (Asp816Val) in the c-kit receptor.
Nonetheless, there was no indications to start treatment for
SM as the patient did not manifest the C symptoms.
The patient achieved a very good partial response after
six cycles of VTD. Following the fourth cycle, the laboratory
work-up revealed leukocytosis (WBC 13.17 G/L), and periph-
eral blood smear still revealed an increased proportion of
eosinophils (17%). The test for the FIP1L1-PDGFRalfa muta-
tion was negative. He remained asymptomatic for cutaneous
or systemic symptoms of SM. The repeated flow-cytometry
analysis of bone marrow found 0.012% of cells with the
following phenotype: CD38++, CD138+++, CD19, CD56+,
CD45, CD27. In addition, 0.205% cells CD117+, HLA-Dr+/,
CD25+, CD2+ were detected (Fig. 2). The patient was proposed
to perform autologous hematopoietic stem cell transplanta-
tion for his MM, but refused. A half year later, he abruptly
progressed with his myeloma. He was admitted to ourti-myeloma therapy (VTD)
is (purple gate). Plasma cells were positive for CD38, CD138,
st cells were not detected.
Fig. 2 – Flow cytometry study of bone marrow aspirate after anti-myeloma therapy (VTD)
The gating strategy used for the identification of the mast cells population (red events, 0.205%) within the CD117+ cells gated
in A and CD25+, CD2+ gated in B. Flow cytometry analysis revealed also approximately 0.012% clonal plasma cells (blue gate)
within CD38+++138+45-56+lambda+ gated in C, D, E.
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anorexia, weight loss and night sweats. Physical examination
showed a moderate ascites. No lymphadenopathy or plasma-
cytomas were observed. Blood examination revealed anemia
(Hb 7.9 g/dL), thrombocytopenia (98 G/L) and elevated WBC
count (28.5 G/L). The patient showed liver dysfunction, ele-
vated LDH and B2-microglobulin levels. SPE showed
a monoclonal peak at 3.9 g/dL. Bone marrow aspirate and
biopsy showed a 72% infiltration of atypical undifferentiated
plasma cells with pleomorphism, prominent nucleoli and
abundant blue cytoplasm. Abdominal ultrasound revealed
significant ascites, lymphadenopathy and hepatosplenome-
galy (liver 174 mm; spleen 151 mm  75 mm). Paracentesis
detected 93% of atypical plasma cells. He started with the
PAD regimen (bortezomib, doxorubicin and dexamethasone).
After one cycle of therapy his clinical condition dramatically
declined and he passed away.
Discussion
A bone marrow biopsy with tryptase staining remains an
initial procedure in multistep diagnosis of SM. Other tests
such as MC immunophenotyping, cytogenetic/molecularstudies, and serum tryptase levels may confirm the final
diagnosis. While patients with ASM and MCL are sympto-
matic, those with ISM frequently present with skin lesions
only and/or mediator-related symptoms. Most adult SM
patients (80%) harbor the KIT D816V mutation, which has
also therapeutic implications [5]. Diagnosis of SM may be
established if one major plus one minor or three minor
criteria are met (Tab. I).
The symptoms of SM are usually grouped into 4 cate-
gories:
 constitutional symptoms such as fatigue, weight loss,
sweats and fever,
 skin symptoms,
 MC mediator-related symptoms,
 musculoskeletal symptoms, which include bone, muscle
and joint pain.
In general, symptoms occurring in mastocytosis are
mainly due to the release of chemicals from the MCs and
thus producing symptoms associated with an allergic
reaction. Flushing and gastric acid hypersecretion due to MC-
associated histamine release are common. Heartburn, sto-
mach aches, abdominal discomfort and diarrhea may occur.
The liver, spleen and lymph nodes may become enlarged in
some patients. Bones may also be affected by mastocytosis
Table I – WHO criteria for systemic mastocytosis
Major criterion Minor criteria
1. Multifocal, dense aggregates of mast cells (15 or more)
detected in sections of bone marrow and confirmed by
tryptase immunohistochemistry or other special stains.
1. In biopsy section, more than 25% of the masts cells in the infiltrate
have atypical morphology, or, of all the mast cells in the aspirate
smear, more than 25% are immature or atypical.
2. Mast cells co-express CD117 with CD2 and/or CD25.
3. Detection of KIT point mutation at codon 816 in bone marrow, blood,
or other extracutaneous organs.
4. Serum total tryptase persistently >20 ng/ml (not a valid criteria in
cases of SM-AHN).
Abbreviations: SM-AHN, systemic mastocytosis with an associated hematologic neoplasm.
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sive SM, cytopenia, osteolysis, lymphadenopathy, hepatome-
galy with impaired liver function, ascites or portal
hypertension, and malabsorption, may also occur.
The difference between indolent and aggressive SM relies
on the presence of C findings, which indicate organ dysfunc-
tion secondary to excessive MC infiltration. C findings
include cytopenias, hepatic dysfunction, pathologic frac-
tures, hypersplenism and gastrointestinal malabsorption [6].
SM-AHN is the second most common subtype of SM
(after ISM), and is a distinct form of SM characterized by
synchronous evolution of two separate clonal populations,
one consisting of MCs and one as a second hematologic
malignancy. Approximately 90% of SM-AHN represent
a myeloid neoplasm such as myelodysplastic syndrome
(MDS), myeloproliferative neoplasms (MPN), MDS/MPN (e.g.,
CMML), eosinophilic disorders, or acute myeloid leukemia
(AML). Lymphoproliferative neoplasms are much less fre-
quently found in this setting. Pardanani et al. reported on
7 patients (5.1%) with lymphoma, 5 patients (3.6%) with
myeloma, and 2 patients (1.5%) with CLL in their study of
138 cases of SM-AHN [6].
The pathophysiologic relationship between SM with
lymphoproliferative disorders remains unclear. In cases of
SM associated with lymphoproliferative disorders, including
plasma cell neoplasm, the D816V C-KIT mutation was
detected in the neoplastic MCs but not in the lymphoid
population, suggesting that SM and coexisting lymphoid
neoplasm were clonally separate [7–10]. Interestingly, there
are several lines of in vitro evidence demonstrating the
ability of neoplastic MCs to support the growth of associated
neoplastic lymphoplasmacytic population [11, 12].
The studies have shown the capacity of neoplastic MCs
to induce the growth of lymphocytic neoplasms. Tournilhac
et al. demonstrated that the human MC line HMC-1 stimu-
lated proliferation of the malignant lymphoplasmacytic cells
of patients with Waldenstrom's macroglobulinemia through
interactions between CD154 on the MCs and CD40 on the
lymphoplasmacytic cells [13]. In vitro studies also suggest
a role of MCs in the growth of HL via their expression of
CD30 ligand [14]. A similar relationship may exist between
MCs and plasma cells as well. MCs secrete multiple cyto-
kines including IL-6 and stem cell factor, both of which have
been shown to induce plasma cell proliferation [15–17].
In summary, the co-existence of SM with MM does occur
rarely. One should be aware of such co-occurrence. Each
patient diagnosed with AHN requires an individual approach.The treatment should be directed against each separate
entity and remains a great challenge. However, this was not
a case in our patient. One may speculate on the potential
pathogenic link between the presence of MCs and develop-
ment and progression of MM, but it requires further studies.
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